This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Results

Authoring team

The benefits of interferon beta-1a treatment included:

  • reduction in relapse rates:
    • 27% for the 22 mcg group
    • 33% for the 44 mcg group

  • prolongation in the time to first relapse:
    • 3 months for the 22 mcg group
    • 5 months for the 44 mcg group

  • time to sustained progression was significantly longer in both treatment groups (p<0.05)

  • disease burden as assessed by T2-weighted MRI scans was significantly lower in both treatment groups

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.